Novel pathogenic variants in CUBN uncouple proteinuria from renal function

• Published in: Journal of translational medicine 2022-10, Vol.20 (1), p.1-480, Article 480
• Main Authors: Gan, Chun, Zhou, Xindi, Chen, Dan, Chi, Huan, Qiu, Jiawen, You, Hui, Chen, Yaxi, Wang, Mo, Yang, Haiping, Jiang, Wei, Li, Qiu
• Format: Article
• Language: English
• Subjects: Albumin; Amnionless; Analysis; Antibodies; Bioinformatics; Biopsy; Blood levels; Cardiovascular diseases; Care and treatment; Cell lines; Complications and side effects; Control; CUBN; Cytoplasm; Diagnosis; DNA sequencing; Filtration; Genetic counseling; Genomes; High density lipoprotein; Identification and classification; Kidney diseases; Laboratory animals; Localization; Microscopy; Nucleotide sequencing; Pathogenic microorganisms; Pathogenic variants; Proteins; Proteinuria; Proximal tubules; Renal function; Transferrin; Urine; Vitamin B deficiency; Vitamin B12
• ISSN: 1479-5876; 1479-5876
• DOI: 10.1186/s12967-022-03706-y

Background Proteinuria is an unfavorable clinical condition highly associated with a risk of renal and cardiovascular disease in chronic kidney disease (CKD). However, whether all proteinuria forms are linked to renal impairment are still unclear. Cubilin is an endocytic receptor highly expressed in renal proximal tubules mediating uptake of albumin, transferrin and [alpha]1-microglobulin. Methods Exome sequencing method initially identified candidate genes. With the application of exome sequencing combined with Sanger sequencing, we further focused on CUBN through bioinformatics analysis. The pathogenic effects of the potentially causative variants were verified utilizing complementary analysis of clinical data and systematic characterization of the variants' expression and function with clinical samples and in vitro experiments in HEK293T cell lines along with in vivo experiments in mice. Results In this study, we identified four novel variants locating after the vitamin B12 (vitB12)-binding domain of Cubilin (encoded by CUBN, NM_001081.3: c.4397G > A (p.C1466Y), c.6796C > T (p.R2266X), c.6821 + 3A > G and c.5153_5154delCT (p.S1718X)) in two families. Moreover, the variants severely affected the expression and function of Cubilin in renal proximal tubules and caused albuminuria, increasing levels in urine transferrin and [alpha]1-microglobulin, but without progressive glomerular filtration barrier (GFB) impairment, vitB12 deficiencies or abnormal blood levels of HDL and albumin. Further mechanistic insights showed that the variants after the vitB12-binding domain of CUBN merely disrupted the association with Amnionless (AMN) that exhibited aberrant localization in cell cytoplasm rather than membrane. Conclusions Here, our findings suggested that different mutation types after the vitB12-binding domain of CUBN uncouple proteinuria from glomerular filtration barrier, that may be an unexpectedly common benign condition in humans and may not require any proteinuria-lowering treatment or renal biopsy. Keywords: Pathogenic variants, CUBN, Amnionless, Proteinuria